No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

GermFlare Announces Its Professional Handheld UVC Light Kills 99.99% of MRSA and P. Aeruginosa in Laboratory Testing

Editor: What To Know

  • “When the user starts to incorporate the use of GermFlare more in their daily routines the risk of being infected by any harmful pathogen decreases noticeable, and it could just be a quick 5-second treatment of any hotspots they touch.
  • Even if the nurse forgets to use rubbing alcohol after they touched a door handle, they do not need to worry because if they used the GermFlare it would have killed the harmful pathogens and broken the chain of infection.
  • The testing parameters were carefully selected to simulated how the effect of the GermFlare would be in the hands of its core user, the healthcare personnel at hospitals.

March 2, 2021

GermFlare, based in Denmark, today proudly reported its handheld UVC light called “GermFlare” to achieve greater than 99.99%, or 4log, inactivation of both Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeruginosa (PA) in less than 5 seconds at a distance of 3.9 inches (10 cm).

Testing on the two bacteria strains was conducted by ALS Denmark A/S (part of ALS Laboratories), an accredited global certified laboratory.

GermFlare, UVC

The testing parameters were carefully selected to simulated how the effect of the GermFlare would be in the hands of its core user, the healthcare personnel at hospitals. GermFlare has previously been proven to inactivate SARS-CoV-2 at the Department of Immunology and Microbiology and Department of Infectious Diseases, Hvidovre Hospital, Denmark.

“Our focus is to provide a solution to the global Hospital Acquired Infection (HAI) problem and as MRSA is one of those bacteria our core users fight against every day, we are very pleased with the results.”

“We hope this test and the results can provide some comfort and confidence to the Healthcare personnel working in areas where there is an increased risk of contracting HAIs.”

“When the user starts to incorporate the use of GermFlare more in their daily routines the risk of being infected by any harmful pathogen decreases noticeable, and it could just be a quick 5-second treatment of any hotspots they touch. Even if the nurse forgets to use rubbing alcohol after they touched a door handle, they do not need to worry because if they used the GermFlare it would have killed the harmful pathogens and broken the chain of infection.” – states Flemming Dahlin, Chief Executive Officer, GermFlare.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy